Pierre Jean Guillausseau
- [Compliance and optimisation of oral antidiabetic therapy. A longitudinal study]Pierre Jean Guillausseau
Service de Medecine B, Hopital Lariboisiere, 2 rue Ambroise Pare, 75010 Paris Université Paris 7
Presse Med 33:156-60. 2004..5 to 56.8%, and increase in percentage of once-daily dosing regimen from 12 to 58.4%...
- Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: a focus on frequency of administrationPierre Jean Guillausseau
Department of Medicine B, Lariboisiere Hospital, University Paris 7 Denis Diderot, Paris, France
Treat Endocrinol 4:167-75. 2005..Therefore, optimization of treatment through a reduction in the frequency of antihyperglycemic administration could be a valuable weapon in the battle to improve health outcomes and reduce the burden of type 2 diabetes...
- Maternally inherited diabetes and deafness: a multicenter studyP J Guillausseau
Department of Medicine B, Lariboisiere Hospital, 2 rue Ambroise Pare, F75010 Paris, University Paris 7 Denis Diderot, France
Ann Intern Med 134:721-8. 2001..Maternally inherited diabetes and deafness (MIDD), which is seen in 0.5% to 2.8% of patients with type 2 diabetes mellitus, is related to a point mutation at position 3243 of mitochondrial (mt) DNA. Its clinical description is incomplete...
- [Compliance to treatment and type 2 diabetes: impact on glycemic balance]Pierre Jean Guillausseau
Presse Med 32:70. 2003
- [Urinary tract infections and diabetes mellitus]Pierre Jean Guillausseau
Service de Medecine B, Hopital Lariboisiere, 75475 Paris
Rev Prat 53:1790-6. 2003..Nosocomial UTI is frequent in such patients. Meticulous preventive measures are the best means of reducing the prevalence of UTI in diabetics...
- [Pathogenesis of type 2 diabetes mellitus]P J Guillausseau
Service de médecine interne B, Hopital Lariboisiere, 2, rue Ambroise Pare, 75475 Paris 10, France
Rev Med Interne 24:730-7. 2003..The lack of compensation is responsible for type 2 diabetes. When permanent hyperglycemia is present, progressive insulin secretory failure with time ensues, due to glucotoxicity and to lipotoxicity...
- [Type II diabetes in children and adults]Pierre Jean Guillausseau
Service de Medecine B, hôpital Lariboisière et faculté de médecine Lariboisière Saint Louis, Universite Paris 7 Denis Diderot, 75475 Paris
Rev Prat 53:1463-71. 2003
- Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practiceP J Guillausseau
Service de Medecine B, Hopital Lariboisiere, Paris et Université Paris 7 Denis Diderot, France
Diabetes Metab 29:79-81. 2003..To address compliance with oral antidiabetic agents and its impact on metabolic control in type 2 diabetic patients treated in general practice...
- 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once dailyP J Guillausseau
Service de Medecine B, Hopital Lariboisiere, 2 rue Ambroise Pare, 75010 Paris, France
Diabetes Metab 27:133-7. 2001..The present study was undertaken to assess the effect of a new formulation of gliclazide administered once daily, gliclazide modified release, on plasma glucose levels over 24 hours...
- Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistanceFranck Mauvais-Jarvis
Department of Endocrinology and Diabetes, Saint Louis Hospital and University of Paris VII School of Medicine, Paris, France
Diabetes 53:645-53. 2004....
- [Drug treatment of type 2 diabetes]Amélie Tielmans
Service de médecine interne B, AP HP, Hopital Lariboisiere, 75010 Paris, France
Presse Med 36:269-78. 2007..GLP-1 (Glucagon-Like Peptide-1) analogs and DPP-IV (dipeptidyl-peptidase-IV) inhibitors are new drug classes currently under development...
- [Drug treatment in type 2 diabetes (part 2)]Amélie Tielmans
Service de médecine interne B, AP HP, Hopital Lariboisiere, Paris
Presse Med 36:467-74. 2007..5%. New guidelines for management of type 2 diabetes were published in 2006...
- Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathyAmelie Lecleire-Collet
Departments of Ophthalmology, Hopital Fernand Widal, Assistance Publique Hopitaux de Paris, Paris 7 University, Paris, France
Invest Ophthalmol Vis Sci 52:2861-7. 2011..To correlate retinal function with vascular response to flicker light in normotensive patients with diabetes without diabetic retinopathy (DR)...
- A possible hypophosphatemia-induced, life-threatening encephalopathy in diabetic ketoacidosis: a case reportBruno Megarbane
Medical Critical Care Department, Lariboisiere Hospital, Paris, France
Am J Med Sci 333:384-6. 2007..Our data strongly suggest that phosphate depletion-induced encephalopathy probably originates from direct impairment of cerebral electrophysiological activity rather than from cardiac flow alteration...
- Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological controlBeatrix Cochand-Priollet
Department of Pathology and Cytopathology, Lariboisiere Hospital, Paris, France
Thyroid 21:1067-73. 2011..We aimed to assess the diagnostic accuracy of immunocytochemistry (ICC) of thyroid FNA to improve its sensitivity and specificity...
- Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trialsNish Chaturvedi
International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College Healthcare NHS Trust, London, UK
Lancet 372:1394-402. 2008..We therefore designed the DIabetic REtinopathy Candesartan Trials (DIRECT) Programme to assess whether candesartan could reduce the incidence and progression of retinopathy in type 1 diabetes...
- Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialAnne Katrin Sjølie
Department of Ophthalmology, Odense University Hospital, Odense, Denmark
Lancet 372:1385-93. 2008..Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabetes...
- PROactive studyPierre Jean Guillausseau
Lancet 367:23; author reply 26-7. 2006